News & Events zu Eastman Kodak Co (KODK)KODKEastman Kodak Co

Kodiak's Zenkuda Shows Significant Results in Diabetic Retinopathy Treatment

Kodiak announced topline results in the GLOW2 Phase 3 superiority study of Zenkuda for the treatment of patients with diabetic retinopathy. In GLOW2, patients were randomized to receive either sham injection or Zenkuda via intravitreal injection at progressively extended intervals after a loading phase, with all patients on 6-month dosing by the end of the study. A total of 62.5% of patients treated with Zenkuda achieved a greater than or equal to 2-step improvement in DRSS score at Week 48, compared with 3.3% in the sham group, meeting the primary endpoint of superiority to sham with high statistical significance. Zenkuda also demonstrated superiority in the two alpha-controlled secondary endpoints, with high statistical significance: Zenkuda demonstrated superiority in the key secondary endpoint of reducing the risk of developing prespecified sight-threatening complications, including new or worsening proliferative DR or center-involving DME, by 85% compared to sham through Week 48. These results support the GLOW1 study results, in which Zenkuda reduced this risk by 89%. Overall,13.7% of patients on Zenkuda achieved a greater than or equal to3-step improvement in DRSS versus 0% with sham, an improvement comparable to GLOW1, in which 5.6% of patients on Zenkuda achieved a greater than or equal to3-step improvement in DRSS versus 0% with sham. Zenkuda was well-tolerated with low rates of common ocular adverse events. Notably, no cases of intraocular inflammation were reported in the study, and no cases of retinal vasculitis or occlusive retinal vasculitis were observed. The incidence of cataract in the study eye was low and in line with expected background rates in patients with DR. Consistent with a real-world diabetic patient population, GLOW2 included patients using GLP-1 medications. These patients were well-balanced between treatment arms. Among patients using GLP-1 medications, Zenkuda achieved a greater than or equal to 2-step improvement in DRSS from baseline to Week 48 in 60% of patients compared with 64.3% in patients not using GLP-1 medications.

Stock Futures Modestly Higher as Market Sentiment Remains Fragile

Stock futures are modestly higher ahead of the open as investors continue to navigate the fallout from the energy shock tied to the conflict involving Iran and the ongoing disruption to oil flows through the Strait of Hormuz. Sentiment remains fragile after a volatile week in which markets repeatedly swung in response to headlines from the Middle East and sharp moves in crude oil.Oil remains the central macro driver and analysts have revised their price expectations higher as disruptions to tanker traffic and energy infrastructure continue to threaten global supply. The International Energy Agency has already announced plans for a large coordinated release of emergency reserves in an attempt to stabilize markets, but traders remain focused on whether supply disruptions will persist. At the same time, the U.S. government has temporarily allowed the sale of previously restricted Russian oil shipments to increase supply and relieve pressure on global markets, highlighting the degree to which energy policy has become intertwined with geopolitical developments.Fund flows this week show investors pulling billions of dollars out of global equity funds while moving capital into cash and short-term bond funds, signaling a shift toward defensive positioning as the geopolitical situation evolves. Volatility has also risen, with the CBOE Volatility Index climbing into the high-20s, underscoring the nervous tone across financial markets.In pre-market trading, S&P 500 futures rose 0.54%, Nasdaq futures rose 0.52% and Dow futures rose 0.55%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Klarnaup 7% after disclosing Michael Moritz, chairman, purchased 3,472,845 ordinary shares between March 3 and March 11 and David Fock, chief product and design officer, purchased 27,000 ordinary shares on March 9ImmunityBioup 4% after completing manufacturing engineering programs, NK2022 and NK2023, establishing a leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer cell therapy platformNioup 3% after HSBC upgraded the stock to Buy with a price target of $6.80UP AFTER EARNINGS -Kodakup 8%Nektarup 2%Rubrikup 2%DOWN AFTER EARNINGS -KinderCare Learningdown 33%EverCommercedown 23%Once Upon a Farmdown 15%Ulta Beautydown 8%ServiceTitandown 6%LOWER -Adobedown 8% after announcing that Shantanu Narayen, who has served as CEO of Adobe for eighteen years, has decided to transition from his position as CEO but will remain as Chair of the Board